Neoadjuvant Radiosurgery for Resectable Brain Metastases

This study is looking at a new way to treat brain metastases (cancers that have spread to the brain) by using radiosurgery (a type of radiation therapy that precisely targets tumors) before surgical removal. The main goal is to see how safe this combined treatment is and to find the best dose of radiosurgery. Researchers also want to know how well this approach prevents brain metastases from growing back. You might be able to join if you are 18 or older, have a specific type of cancer (not small cell lung cancer, lymphoma, or germ cell tumors), and have 1-4 brain metastases that can be treated with both radiosurgery and surgery. The study is currently unclear on its recruitment status.

Study design: This is a Phase I/II study with a planned enrollment of 36 participants. It starts with a Phase I to find the safest dose of radiosurgery, followed by a Phase II to see how well it works.
What's involved: Participants will undergo radiosurgery and surgical resection. They will also have quality-of-life assessments.
Compensation: Not stated in the trial record.
Follow-up: The study will follow participants for up to 3 years to see if the brain metastases return.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Recruiting

PHASE1Ages 18+InterventionalTreatment

Case Comprehensive Cancer Center

~36 participants

Updated 2026-08-06 on ClinicalTrials.gov

What's tested:radiosurgerytherapeutic conventional surgeryquality-of-life assessment

At a glance

Recruiting sites

1 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Maximum tolerated dose (MTD)

Measured over Day 0

+1 more outcome measured

Conditions

Tumors Metastatic to Brain

Where it's being run

2 sites across 1 states

Ohio2

Study leadership

Erin Murphy, MD · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center

Who to contact

Erin Murphy, MD

[email protected]

1-866-223-8100

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Have a prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies

Magnetic resonance imaging (MRI) evidence of 1-4 brain metastases, with at least one lesion \> 20 mm and ≤ 50 mm in maximal diameter and determined to be appropriate for SRS and gross total resection; all other brain metastases are appropriate for SRS

Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection

Patient must have a Karnofsky performance score of ≥ 70

Exclusion

Patient deemed medically unfit to undergo surgical resection of brain metastasis

Prior whole brain radiotherapy

Patient with contraindication for imaging with MRI

Inability to participate in study activities due to physical or mental limitations

Inability or unwillingness to return for all the required follow-up visits

At the time of planning, unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm

Tumor located in the brainstem

Imaging or cytologic evidence of leptomeningeal disease

What this trial measures

Maximum tolerated dose (MTD)Day 0
MTD of radiosurgery determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (Phase I)
Proportion of participants without local failure (Phase II)Up to 3 years
Local control of brain metastases, as measured by proportion of participants without local failure (Local failure is tumor progression of the metastasis treated on the study) (Phase II) The Kaplan-Meier method will be used.

Trialytics